Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rigel Pharmaceuticals excels in sales, faces awareness challenges ahead

Rigel Pharmaceuticals demonstrated strong sales performance and efficient cost management in Q4 2022.
The company faces challenges in raising awareness, maintaining persistency, and reaching profitability.
Exploring market opportunities, partnerships, and collaborations position Rigel for future growth.
Competitive trial results and a focus on persistency drive Rigel's competitive edge in the market.

Rigel Pharmaceuticals excels in Q1 with REZLIDHIA and TAVALISSE, faces prescribing behavior challenges

Rigel Pharmaceuticals showcased strong Q1 performance, particularly with REZLIDHIA and TAVALISSE, while facing challenges in understanding prescribing behavior.
The company's focus on differentiated positioning, academic-community growth, and strategic partnerships presents promising opportunities for future expansion.
Financial stability, positive clinician feedback, and ongoing pipeline advancements position Rigel well for continued growth and success in the market.

Rigel Pharmaceuticals reports robust Q2 sales and strategic growth focus

Rigel Pharmaceuticals showcased strong sales performance and product efficacy in Q2, positioning for future growth.
Challenges in managing expenses and strategic decision-making require careful navigation for sustained profitability.
Exploration of new opportunities and continued focus on innovation present avenues for revenue growth and market expansion.
Financial stability, ongoing development programs, and positive market feedback underpin Rigel's strategic direction and growth potential.

Rigel Pharmaceuticals excels in Q3 sales, eyes pipeline expansion

Rigel Pharmaceuticals demonstrated robust sales growth in Q3, managed expenses effectively, and aims for financial breakeven through operational efficiency. The company's strategic focus on pipeline expansion and partnerships positions it well for future growth and innovation.

Rigel Pharmaceuticals posts record sales, eyes growth with Gavreto acquisition

Rigel Pharmaceuticals reported strong financial performance with record sales and net income in Q4 2023.
The acquisition of Gavreto presents growth opportunities in the oncology market.
Challenges include transitioning Gavreto to commercial operations and competition in the targeted therapy space.

Rigel Pharmaceuticals reports strong Q1 performance and growth opportunities

Rigel Pharmaceuticals demonstrated strong performance in Q1 2024 with robust demand for key products and strategic acquisitions.
While facing challenges such as inventory management and financial breakeven, the company is well-positioned for growth.
Opportunities lie in continued sales growth, clinical advancements, and portfolio expansion through in-licensing deals.

Rigel Pharmaceuticals excels in Q2 with strong sales and pipeline progress

Rigel Pharmaceuticals delivered a robust performance in Q2 2024, driven by commercial success, pipeline advancements, and financial discipline. While facing challenges in clinical trial strategies and competitive landscape, the company is well-positioned to capitalize on growth opportunities through product expansions and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif. , May 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present on Wednesday, June 7, 2023 at 2:30 p.m.

Rigel to Present at the Jefferies 2023 Global Healthcare Conference

Atai Life Sciences BV

Sorrento Therapeutics Inc

When it comes to investing, penny stocks often evoke a sense of intrigue and opportunity. These low-priced securities, typically traded under $5 per share, can potentially deliver substantial gains quickly.

3 Penny Stocks to Make You the Millionaire Next Door

AMN Healthcare Services

Murphy USA

Patrick Industries

Caesars Entertainment

Paratek Pharma

Winnebago

Although the equities sector recovered reasonably well from 2022's harsh glare, rising headwinds force consideration of cheap growth stocks to buy now. Essentially, some enterprises with upside potential may be overlooked by other investors, presenting contrarian opportunities.

7 Growth Stocks That Are Too Cheap to Ignore Right Now

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and Chief Financial Officer Conference Call Participants Eun Yang - Jefferies Carly Kenselaar - Citi Allison Bratzel - Piper Sandler Kalpit Patel - B.

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2023 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.16 per share a year ago.

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE® net product sales of $22.3 million and REZLIDHIA® net product sales of $1.5 million Global expansion of TAVALISSE in ITP with Japanese launch by partner Kissei Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports First Quarter 2023 Financial Results and Provides Business Update

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability.

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability

SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close on Tuesday, May 2, 2023.

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

Ardelyx

iBio

OPKO Health

4 biotech penny stocks to watch right now. The post 4 Top Penny Stocks To Watch With Big Biotech News This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Watch With Big Biotech News This Quarter

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Commercial Officer Wolfgang Dummer - EVP and Chief Medical Officer Dean Schorno - EVP and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citi Eun Yang - Jefferies Do Kim - Piper Sandler Kristen Kluska - Cantor Fitzgerald Gary Nachman - BMO Capital Markets Joe Pantginis - H.C.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call Transcript

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates

Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch continues to progress and is supported by recent addition to NCCN Guidelines® for AML Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023.

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update

˗  REZLIDHIA induced durable remissions in adult patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication of data in Blood Advances, which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™ (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1)1, in patients with mIDH1 relapsed or refractory acute myeloid leukemia (R/R AML).

Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances

GlaxoSmithKline

23andMe

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

3 Penny Stocks That Could Make You Filthy Rich

SOUTH SAN FRANCISCO, Calif. , Jan. 18, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA ™ (olutasidenib) has been added by the National Comprehensive Cancer Network® (NCCN®) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for acute myeloid leukemia (AML).

National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

In terms of product sales, RIGL has been a one drug company with Tavalisse in immune thrombocytopenia. The recent approval of Rezlidhia opens the door for investors to track the growth of another drug, a new source of excitement.

Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023

SOUTH SAN FRANCISCO, Calif. , Dec. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated approach to treating lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Dec. 15, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it dosed the first patient in its Phase 1b study of R289, an IRAK1/4 dual inhibitor, in patients with lower-risk myelodysplastic syndromes (MDS) who are refractory or resistant to prior therapies.

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

ST. LOUIS, Mo.--( BUSINESS WIRE )--Optime Care, a member of the AscellaHealth Family of Companies , today announced a contractual partnership with Rigel Pharmaceuticals, Inc., bringing its full suite patient support/HUB service capabilities to support Rezlidhia™(olutasidenib), a recent FDA-approved treatment for adult patients with relapse or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Optime Care's services for life sciences manufacturers include pre-commercialization and market access expertise, exclusive distribution partnerships, national medication fulfillment and high-touch patient support and HUB services for enhanced patient outcomes.

Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ Patients

Akebia Therapeutics

The Beachbody Co.

ComSovereign Holding

Faraday Future Intelligent Electric

Nymox Pharmaceutical

Sonim Technologies Inc

Statera Biopharma Inc

Tricida Inc

Titan Medical Inc

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 This Week

eHealth

Eos Energy Enterprises

Vivani Medical Inc

Y-Mabs Therapeutics Inc

Penny stocks to buy according to analysts in December 2022. The post 5 Penny Stocks To Buy According To Analysts, Price Targets Up To 919% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts, Price Targets Up To 919%

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 7 Under $1 To Watch Now

Best Penny Stocks To Buy? 4 Under $1 To Watch Now

Ambev

Cosmos Holdings

Use these tips for trading penny stocks right now The post Don't Invest in Penny Stocks Until You've Read This Article appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Rigel Pharmaceuticals Stock (RIGL)